Status
Conditions
Treatments
About
The objective of this study is to describe the observed safety profile of Xospata® 40 mg tablet when administered in patients with relapsed or refractory AML with FLT3 mutation in routine clinical practice in Korea.
Full description
This study is being mandated by Ministry of Food and Drug Safety (MFDS) as a part of the Korea-Risk Management Plan (K-RMP) to assess safety in patients with relapsed or refractory AML with FLT3 mutation in routine clinical practice in Korea. This study collects data for 54 months according to the purpose of this study in routine clinical practice as an observational study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
33 participants in 1 patient group
Loading...
Central trial contact
Astellas Pharma Korea, Inc.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal